Copertina

Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xiaotong Hu, Hongda Lin, Yan Huang, Pingsheng Xu, Bin Xu, Haibin Yu, Meixia Wang, Sheng Feng, Yijing Li, Kai Shen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	The Journal of Clinical Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment
di: Raj Vuppalanchi, et al.
Pubblicazione: (2024)

Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
di: Annie Lumen, et al.
Pubblicazione: (2024)

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib
di: Martha Gonzalez, et al.
Pubblicazione: (2025)

Insights Into Aldosterone Regulation Through Pharmacokinetic–Pharmacodynamic Modeling of an Aldosterone Synthase Inhibitor
di: Javiera Cortés‐Ríos, et al.
Pubblicazione: (2025)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
di: Jatinder Kaur Mukker, et al.
Pubblicazione: (2025)

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
di: Megumi Iwai, et al.
Pubblicazione: (2025)

Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment
di: Islam R. Younis, et al.
Pubblicazione: (2024)

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
di: Yan‐ou Yang, et al.
Pubblicazione: (2025)

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor
di: Sharif I. Soleman, et al.
Pubblicazione: (2024)

A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
di: Wei Zhu, et al.
Pubblicazione: (2026)

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
di: Katharina Erb‐Zohar, et al.
Pubblicazione: (2024)

Physiologically Based Pharmacokinetic Modeling of Lemborexant: Exploration of Doses for Populations with Hepatic Impairment
di: Wanhong Wu, et al.
Pubblicazione: (2025)

Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Proline Henagliflozin in Chinese Subjects with Varying Degrees of Liver Dysfunction
di: Likun Ding, et al.
Pubblicazione: (2024)

Indomethacin Pharmacokinetics and Pharmacodynamics in Pregnancies With Preterm Labor: The Need for Dose‐Ranging Trials
di: Stephen J. Balevic, et al.
Pubblicazione: (2024)

Characterizing the Nonlinear Pharmacokinetics and Pharmacodynamics of BI 187004, an 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Humans by a Target‐Mediated Drug Disposition Model
di: Xuanzhen Yuan, et al.
Pubblicazione: (2024)

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients
di: Eleanor A. Lisbon, et al.
Pubblicazione: (2025)

Clinical Impact of Hepatic Impairment on the Pharmacokinetics of Sotorasib and Its Major Metabolites: Implications for Dose Adjustment
di: Mason McComb, et al.
Pubblicazione: (2025)

Dose Optimization of BIIB107, an Anti‐Alpha‐4 Integrin Monoclonal Antibody, Through Population Pharmacokinetic and Pharmacodynamic Modeling
di: Marie Toukam, et al.
Pubblicazione: (2025)

Guiding Dyslipidemia Treatment: A Population Pharmacokinetic–Pharmacodynamic Framework for Obicetrapib
di: Allison Dunn, et al.
Pubblicazione: (2024)

Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy
di: Xiaomei I. Liu, et al.
Pubblicazione: (2025)

FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
di: Million A. Tegenge, et al.
Pubblicazione: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
di: Titia Q. Ruijs, et al.
Pubblicazione: (2024)

Extrapolation of Midazolam Disposition in Neonates Using Physiological‐Based Pharmacokinetic/Pharmacodynamic Modeling
di: Tangping Zhao, et al.
Pubblicazione: (2025)

Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
di: Pamela Navarro‐Gonzales, et al.
Pubblicazione: (2024)

Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage Dosing
di: Gauri G. Rao, et al.
Pubblicazione: (2024)

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients
di: Yawen Yuan, et al.
Pubblicazione: (2024)

Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults
di: Maciej Gasior, et al.
Pubblicazione: (2024)

Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study
di: Riccardo Perfetti, et al.
Pubblicazione: (2024)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants
di: Assem el Baghdady, et al.
Pubblicazione: (2024)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Pubblicazione: (2024)

Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation
di: Katie B. Olney, et al.
Pubblicazione: (2024)

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease
di: Islam R. Younis, et al.
Pubblicazione: (2025)

Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist
di: Akihito Ogasawara, et al.
Pubblicazione: (2024)

Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01‐0371) in Adult Patients with Pulmonary Tuberculosis
di: Sang Min Lee, et al.
Pubblicazione: (2024)

Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Secukinumab: Dose Exploration in Pediatric Patients with Plaque Psoriasis
di: Liu Zhiwei, et al.
Pubblicazione: (2025)

Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers
di: Yi Chien Chang, et al.
Pubblicazione: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults
di: Caroline A. Lee, et al.
Pubblicazione: (2024)

Physiologically Based Pharmacokinetic Modeling of Lurasidone, an Antipsychotic Drug: Impact of CYP3A4 Polymorphisms and Hepatic Impairment on Exposure and Dose Optimization
di: Seung‐Hyun Jeong, et al.
Pubblicazione: (2026)

Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer
di: Xiaofei Zhou, et al.
Pubblicazione: (2025)

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation
di: Lukas K. van Vugt, et al.
Pubblicazione: (2025)